Organization: AEterna Zentaris Inc

AEterna signs collaborative deal with sanofi-aventis

Quebec City-based AEterna Zentaris Inc has entered a major collaborative agreement with sanofi-aventis to develop, commercialize and license Cetrorelix — its drug compound for the treatment of benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate. The terms of the agreement are for the US market, where more than 20 million men suffer from…

AEterna sells Utah subsidiary for $3.2 million

Quebec City-based AEterna Zentaris Inc has sold its Salt Lake City UT-based subsidiary, Echelon Biosciences Inc, to Frontier Scientific Inc, Logan UT, for $3.2 million. The sale of the subsidiary will allow AEterna to focus on its core strengths in endocrine therapy and oncology and advance its lead development programs….